# US 2020/0390768 A1 · Salt of fused heterocyclic derivative and crystal thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390768 A1
- Document ID: US20200390768A1
- Status: Published application
- Kind: A1
- Application number: 16/747,603
- Filed: 2020-01-21
- Published: 2020-12-17
- Earliest claimed: 2010-02-10
- Assignees: Kissei Pharmaceutical Co., Ltd.
- Applicants: Kissei Pharmaceutical Co., Ltd.
- Inventors: Kazumichi JO; Hideki TAKEUCHI
- Web page: https://patentgrep.com/patent/US20200390768A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/14: Quaternary ammonium compounds, e.g. edrophonium, choline (betaines A61K31/205)
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 5/04: for decreasing, blocking or antagonising the activity of the hypothalamic hormones
- A61P 5/06: of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P 5/08: for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
- A61P 5/24: of the sex hormones
- A61P 13/08: of the prostate
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/02: for disorders of the vagina
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 15/10: for impotence
- A61P 15/16: Masculine contraceptives
- A61P 15/18: Feminine contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/10: Anti-acne agents
- A61P 17/14: for baldness or alopecia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 211/63: having quaternised nitrogen atoms bound to acyclic carbon atoms
- C07D 495/04: Ortho-condensed systems
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention provides 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyl-oxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid choline salt having excellent solubility and storage stability.

## Claims

### Claim 1

A method for preventing or treating a sex hormone-dependent disease in a subject, said method comprising administering to said subject a therapeutically effective amount of a compound represented by the formula:

### Claim 2 (depends on 1)

The method of claim 1, wherein said sex-hormone dependent disease is selected from the group consisting of benign prostatic hypertrophy, hysteromyoma, endometriosis, metrofibroma, precocious puberty, amenorrhea, premenstrual syndrome, dysmenorrhea, polycystic ovary syndrome, lupus erythematosis, hirsutism, short stature, sleep disorders, acne, baldness, Alzheimer's disease, infertility, and irritable bowel syndrome.

### Claim 3 (depends on 1)

The method of claim 1, wherein said sex-hormone dependent disease is a cancer.

### Claim 4 (depends on 3)

The method of claim 3, wherein said cancer is selected from the group consisting of prostate cancer, ovary cancer, uterine cancer, and breast cancer.

### Claim 5 (depends on 1)

The method of claim 1, wherein said compound is administered orally.

### Claim 6 (depends on 1)

The method of claim 1, wherein said subject is a human.

### Claim 7 (depends on 1)

The method of claim 1, wherein said compound is crystalline.

### Claim 8 (depends on 7)

The method of claim 7, wherein said compound exhibits characteristic peaks at diffraction angles (2θ(°)) of 7.1, 11.5, 19.4, 20.3, 21.5, 22.0, 22.6, 23.5, and 26.2 in a powder X-ray diffraction diagram.

### Claim 9 (depends on 7)

The method of claim 7, wherein said compound is characterized by an X-ray powder diffraction spectrum substantially as depicted in FIG. 1.

### Claim 10 (depends on 7)

The method of claim 7, wherein said compound exhibits characteristic peaks at chemical shift values (δ(ppm)) of 155.8, 149.8, 145.3, 118.0, 113.7, 111.6, 110.3, 98.1, 69.8, 58.7, 57.1, and 55.5 in a 13C solid-state nuclear magnetic resonance (NMR) spectrum.

### Claim 11 (depends on 7)

The method of claim 7, wherein said compound is characterized by a 13C solid-state NMR spectrum substantially as depicted in FIG. 3.

### Claim 12 (depends on 7)

The method of claim 7, wherein said compound exhibits characteristic peaks at chemical shift values (δ(ppm)) of −131.6, −145.2, and −151.8 in a 19F solid-state NMR spectrum.

### Claim 13 (depends on 7)

The method of claim 7, wherein said compound is characterized by a 19F solid-state NMR spectrum substantially as depicted in FIG. 5.

### Claim 14 (depends on 7)

The method of claim 7, wherein said compound exhibits an endotherm at about 213° C. as measured by differential thermal analysis.

### Claim 15 (depends on 7)

The method of claim 7, wherein said compound is characterized by a differential thermal analysis curve substantially as depicted in FIG. 2.

### Claim 16 (depends on 7)

The method of claim 7, wherein said compound is characterized by a thermogravimetric analysis curve substantially as depicted in FIG. 2.

### Claim 17 (depends on 1)

The method of claim 1, said method comprising administering to said subject a pharmaceutical composition comprising said therapeutically effective amount of said compound.

### Claim 18 (depends on 17)

The method of claim 17, wherein said pharmaceutical composition is a tablet or capsule.
